Activation of glial cells and neuro-glial interactions are emerging as key mechanisms underlying chronic pain. Accumulating evidence has implicated 3 types of glial cells in the development and maintenance of chronic pain: microglia and astrocytes of the central nervous system (CNS), and satellite glial cells of the dorsal root and trigeminal ganglia. Painful syndromes are associated with different glial activation states: (1) glial reaction (ie, upregulation of glial markers such as IBA1 and glial fibrillary acidic protein (GFAP) and/or morphological changes, including hypertrophy, proliferation, and modifications of glial networks); (2) phosphorylation of mitogen-activated protein kinase signaling pathways; (3) upregulation of adenosine triphosphate and chemokine receptors and hemichannels and downregulation of glutamate transporters; and (4) synthesis and release of glial mediators (eg, cytokines, chemokines, growth factors, and proteases) to the extracellular space. Although widely detected in chronic pain resulting from nerve trauma, inflammation, cancer, and chemotherapy in rodents, and more recently, human immunodeficiency virus-associated neuropathy in human beings, glial reaction (activation state 1) is not thought to mediate pain sensitivity directly. Instead, activation states 2 to 4 have been demonstrated to enhance pain sensitivity via a number of synergistic neuro-glial interactions. Glial mediators have been shown to powerfully modulate excitatory and inhibitory synaptic transmission at presynaptic, postsynaptic, and extrasynaptic sites. Glial activation also occurs in acute pain conditions, and acute opioid treatment activates peripheral glia to mask opioid analgesia. Thus, chronic pain could be a result of ''gliopathy,'' that is, dysregulation of glial functions in the central and peripheral nervous system. In this review, we provide an update on recent advances and discuss remaining questions.
Introduction
It is now well established that chronic pain, such as inflammatory pain, neuropathic pain, and cancer pain, is an expression of neural plasticity, both in the peripheral nervous system (PNS) as peripheral sensitization [11, 78] and in the central nervous system (CNS) as central sensitization [111, 139] . The most widely studied neuronal mechanisms are hyperexcitability and sensitization of primary sensory neurons (peripheral sensitization) and enhancement of excitatory synaptic transmission in spinal cord, brainstem, and cortical neurons (central sensitization), caused by transcriptional, translational, and post-translational regulation. Other neuronal mechanisms include disinhibition (reduced inhibitory synaptic transmission), descending pathway facilitation (eg, from the brainstem to the spinal cord), and long-term potentiation (LTP) in the cortex and spinal cord. These neuronal mechanisms have been strongly implicated in the development and maintenance of persistent pain in rodents [11, 142, 195, 205, 317] . Central sensitization and LTP are also involved in human pain conditions [134, 285] . In parallel to the progress in these neuronal mechanisms is the increased recognition of the importance of non-neuronal cells, especially glial cells, in the initiation and maintenance of chronic pain. Of note, over the last 10 years, the field of pain research has witnessed a dramatic increase in the number of publications studying glia and pain. Numerous reviews have been published in high-impact journals to address this topic [24, 52, 68, 80, 160, 164, 200, 209, 247, 273] . Here we provide a comprehensive and updated review of glia and pain by integrating recent advances in both the pain and glial research fields.
Glial cells in the CNS consist of 3 major groups: astrocytes, microglia, and oligodendrocytes [69] . Glial cells in the PNS consist of satellite glial cells (SGCs) in the dorsal root ganglia (DRGs) and trigeminal ganglia (TGs) and Schwann cells in the peripheral nerves. This review will cover 3 types of glia-microglia,
